ODM-212

DRUG2 trials

Sponsors

Orion Corporation, Orion Pharma

Conditions

MesotheliomaNSCLC (Advanced Non-small Cell Lung Cancer)Pancreatic CancerSolid Tumours

Phase 1

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

RecruitingNCT06725758

Orion Corporation, Orion PharmaSolid Tumours

Start: 2023-10-26End: 2027-12-31Target: 315Updated: 2026-05-08

A 2-part Phase 1/2 Open-label Trial on ODM-212

RecruitingNCT07563738

Orion Corporation, Orion PharmaMesothelioma, NSCLC (Advanced Non-small Cell Lung Cancer), Pancreatic Cancer

Start: 2026-03-27End: 2029-09-01Target: 229Updated: 2026-05-04

Related Papers

Abstract 3005: <i>Ex vivo</i> trial of ODM-212, a novel pan-TEAD inhibitor, in patients with primary and metastatic solid tumors

Cancer Research2026-04-03